4 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 1 | Recruiting 1 |
Follow VS-7375: new trials by email Literature Review of VS-7375 trials Research Report on VS-7375
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer VS-7375, cetuximab, panitumumab - Colorectal Cancer | Phase 2 | Recruiting | Verastem, Inc. | 150 | 2026-07-28 | 2026-10-26 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer VS-7375 - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Verastem, Inc. | 105 | 2026-07-22 | 2026-10-23 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) - Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | Phase 2 | Recruiting | Verastem, Inc. | 185 | 2026-06-16 | 2026-10-23 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Verastem, Inc. | 616 | 2025-06-24 | 2026-10-23 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Appendiceal Neoplasms (1) · Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Verastem, Inc. (4)
Australia (4) · United States (4) · Puerto Rico (2) · Canada (1) · France (1) · Spain (1)